Regeneron Pharmaceuticals is a biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative medicines for serious medical conditions. The company is renowned for its cutting-edge research in areas such as genetics, biochemistry, and biology, which has led to the development of a range of therapies for diseases including cancer, eye disorders, and inflammatory conditions. Regeneron's commitment to scientific advancement and collaboration propels its pipeline of novel treatments, aimed at improving patient outcomes and addressing unmet medical needs on a global scale. Read More
Shares of biotech company Regeneron (NASDAQ:REGN)
fell 9.6% in the morning session after the company reported weak first-quarter 2025 results. Its revenue missed significantly, and its EPS fell short of Wall Street's estimates. Revenue declined 4% from the prior year, as Regeneron struggled to offset the double-digit decline in net product sales, including a 29% plunge in legacy EYLEA, despite a 54% jump in EYLEA HD. Overall, this quarter could have been better.
Stay informed about the performance of the S&P500 index in the middle of the day on Tuesday. Uncover the top gainers and losers in today's session for valuable insights.
Looking for the S&P500 stocks that are experiencing notable gaps on Tuesday? Find out which stocks are gapping up and gapping down in the S&P500 index during today's session.
Wall Street modestly up as investors await economic data and corporate earnings. Bond market continues rally, gold and oil prices fall.Wall Street rises modestly, bond market continues rally, gold and oil prices fall as investors await economic data and corporate earnings.
Before the opening bell on Tuesday, let's take a glimpse of the US markets and explore the S&P500 top gainers and losers in today's pre-market session.
Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.7% year on year to $3.03 billion. Its non-GAAP profit of $8.22 per share was 3% below analysts’ consensus estimates.
TARRYTOWN, N.Y., April 29, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the first quarter of 2025 and provided a business update.
Biopharma stocks rally along with many of our SMID cap trades. The market situation with pharmaceuticals is even more complicated because we started off with legislation (the IRA) trying to curb rising drug and healthcare costs.
The agreement is to manufacture and supply bulk drug products of Regeneron’s commercial biologic medicines at Fujifilm’s Holly Springs, North Carolina, campus for a period of 10 years.
New manufacturing and supply agreement with FUJIFILM Diosynth Biotechnologies in North Carolina will enable additional production of Regeneron’s biologic medicines and support high-paying jobs in the region
TARRYTOWN, N.Y., April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the supplemental Biologics License Application (sBLA) for the addition of extended dosing intervals (up to every 24 weeks) for EYLEA HD® (aflibercept) Injection 8 mg across all approved indications.
